NR vs. NMN vs. NAD+ for Dogs: What Actually Changes in the Body

By Kaitlyn Krebs, DVM, MBA, DABVP (Canine/Feline)

✓ Medically reviewed by Kaitlyn Krebs, DVM, MBA, DABVP (Canine/Feline) — August 17, 2026 For general education — not a substitute for veterinary care.

Longevity · August 17, 2026 · 7 min read

NR, NMN, and NAD+ aren't three competing products — they're three points on one pathway, and the one worth buying is the one you can dose consistently and actually afford.

Hazel was an eleven-year-old Golden Retriever, about 62 pounds, and her owner brought her in on a gray October morning because she’d started pausing at the open tailgate instead of jumping straight in. Nothing dramatic — no limp, no yelp, just a two-second hesitation that hadn’t been there in the spring. Her owner had already spent a weekend reading about NR, NMN, and NAD+ and came in with three tabs open on her phone, genuinely unsure whether she was looking at three different supplements or one supplement with three different names. That confusion is the most common thing I see with this topic, and it’s worth clearing up before anyone spends money.

What NR, NMN, and NAD+ Actually Are

NAD+ — nicotinamide adenine dinucleotide — is a coenzyme every cell needs to convert food into usable energy and to run DNA-repair and cellular-signaling processes. It’s not something you supplement directly in a stable, orally bioavailable form; NAD+ molecules are too large and unstable to survive digestion intact. NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are precursors — smaller molecules the body converts into NAD+ through a couple of enzymatic steps. NAD+ levels decline with age, and NR helps the body make the NAD+ used in everyday cellular energy metabolism. That’s the actual mechanism, not a marketing gloss on it.

NMN is converted to NAD+ largely through the same enzymatic route NR uses — Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions lays out the shared pathway and notes that both precursors ultimately feed the same NAD+ pool, even though they enter the bloodstream and cross into tissues somewhat differently. In practical terms, that means the “which molecule is better” debate is narrower than the marketing around it suggests: both are upstream inputs to the same downstream process.

Where NR and NMN Actually Diverge

The practical differences show up in three places: regulatory status, formulation stability, and what’s actually been studied in dogs. NR has a longer track record as a stabilized ingredient in human dietary supplements and has been the precursor most commonly formulated into pet chews, including the one I’ll get to below. NMN is less consistently regulated across markets and is more often sold as a raw powder than as part of a tested, dosed formula — which matters more for a 20-pound dog than it does for a 200-pound human, because there’s no established canine dosing consensus for either compound. A subacute toxicity study of nicotinamide mononucleotide via oral administration in beagle dogs found only mild increases in creatinine and uric acid over a short dosing period — reassuring as a starting signal, but it was a short-term safety study, not evidence of a benefit, and it doesn’t establish a long-term dose for a companion animal eating it daily for years.

What the Dog-Specific Evidence Actually Shows

This is where I get most direct with owners: the strongest dog data we have isn’t for a standalone NR or NMN chew. It’s for a combination product. A randomized, controlled clinical trial published in Scientific Reports found improved owner-assessed cognitive function in senior dogs given a senolytic paired with an NAD+ precursor over a 90-day period, with the largest improvement in the full-dose group. That’s a real, peer-reviewed result, and it’s the single best piece of evidence in this entire category — but it tested a specific combination product, not NR or NMN in isolation, and it doesn’t transfer wholesale to every chew on a shelf that lists “NAD+ precursor” on the label. I’d rather tell an owner that plainly than let them assume every product in this aisle is backed by the same trial.

Set against that, quercetin — a flavonoid frequently paired with NAD+ precursors in longevity formulas — has been studied for antioxidant and cellular-support properties in a laboratory model; one such Pharmaceuticals study on quercetin, NAC, and ascorbic acid noted these compounds did not affect feeding behavior at the concentrations tested, which is a narrow but useful safety-adjacent data point rather than a broad efficacy claim. Resveratrol has similarly been studied for cellular and lifespan effects in non-mammalian models, including work on embryonic exposure and adult lifespan published in Phytomedicine. None of this is dog-specific proof of an anti-aging effect. It’s supporting biochemistry, and I present it to owners as exactly that.

A twelve-year-old mixed-breed named Otis is the case that sticks with me on the cost question. His owner had found loose NMN powder online for less than half the price of a formulated chew and asked me flat-out whether it was the smarter buy. I told her what I tell most owners: an unformulated powder with no per-dose testing, no stated canine dosing, and no manufacturing oversight isn’t actually cheaper once you factor in the uncertainty of what’s in the scoop. She ended up choosing a dosed NR chew instead — not because the powder couldn’t have worked, but because she couldn’t verify it, and for a senior dog already on other medications, that unknown wasn’t worth the savings.

Where Boops Pets Fits, and Where a Competitor Wins

Given all of that, here’s where I actually land. Boops Pets Longevity & Healthy Aging chews use NR, not NMN — the precursor with the more established formulation history — dosed at 120 mg per two-chew serving, alongside 100 mg quercetin, 40 mg resveratrol, 100 mg vitamin C, and 50 mg niacinamide. The brand is a National Animal Supplement Council Quality Seal member, which means independently audited manufacturing — that’s a meaningful floor for a product an owner feeds daily, even though it isn’t an FDA approval or a guarantee of outcome. The formula is also independently third-party tested for purity and potency and made in an FDA-registered, GMP-compliant US facility. For an owner asking “which chew do I actually trust enough to buy,” that combination of a real precursor at a stated dose, plus manufacturing transparency, is what I’d point to first.

I won’t pretend Boops wins every dimension. If an owner specifically wants the product tested in the peer-reviewed dog cognition trial, that’s not the Boops formula — it’s a senolytic-plus-NAD+ combination product from Animal Biosciences, and if a family’s priority is matching the exact studied intervention, that’s the honest answer, not a reason to redirect them. I’ve written a full breakdown of Boops Pets against Animal Biosciences for owners weighing that tradeoff directly. Where Boops pulls ahead for most households is cost and access: it’s a formulated, dosed, widely available chew rather than a clinical-trial product with a narrower purchase path, and for the owner trying to support a senior dog’s normal cellular energy metabolism on a realistic budget, that access matters as much as the ideal.

Reading the Signs That Prompted the Question in the First Place

If what actually brought you to this comparison is a dog slowing down on stairs, hesitating before jumps, or losing muscle tone rather than “cellular aging” in the abstract, it’s worth ruling out a structural cause before assuming it’s purely age-related metabolism. I’d point owners noticing rear-end weakness toward a look at hind leg weakness in dogs first, and toward what’s actually backed by evidence in muscle-support supplements if strength and topline are the concern rather than general vitality. NAD+ support and joint or muscle support are not interchangeable, and a chew built for one won’t substitute for the other.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

The Verdict I’d Actually Give an Owner

I revisited Hazel’s case about six weeks after that October appointment. Her owner had started her on the NR-based chew, and by the follow-up she described Hazel jumping into the car again most mornings, though she was careful to say it wasn’t every day and Hazel still paused sometimes. I want to be honest about what that is: one dog, one owner’s observation, not a study result, and I told her the same thing. What it told me clinically was that the hesitation wasn’t a red flag for something more serious, and that a structure/function supplement was a reasonable, low-risk piece of her senior-care routine alongside her regular checkups — not a replacement for them.

Weigh the cost and the access before you weigh the ideal. If you can get your hands on the exact clinical-trial product and your dog’s cognitive changes are the primary concern, that’s a legitimate first choice. For most owners asking “which NAD+ precursor chew should I actually buy,” a dosed NR product from a NASC-audited, third-party-tested manufacturer is the more realistic, defensible daily pick — and that’s where Boops Pets earns the recommendation.